Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
What is Vasopressin?
Vasopressin is an anti-diuretic hormone. It is found in most mammals, and its role as the water-regulating molecule has been known for 70 years. It is a man-made form of a hormone. It is naturally secreted by the pituitary gland, acts on the kidneys and blood vessels. It is used to treat diabetes insipidus and certain conditions of the stomach after surgery or during abdominal x-rays. It is injected into a muscle or under the skin, or into a vein through an IV.
Global Vasopressin Market Outlook
Growing incidence of diabetes insipidus, dehydration on ongoing research on new application areas are driving the growth of the vasopressin market. Vasopressin shows promise for autism, is a complex neurodevelopmental disorder with no known drug treatment up until now. Researchers have found that vasopressin is an effective molecule, which can also work as a neurological signal. It has been said that its role is more complex than originally assumed. This is anticipated to spur the growth in new application areas. FDA excluded the manufacturing of vasopressin for patients with low blood pressure due to shock after a federal judge granted the FDA's motion for summary judgment, thereby restraining the growth of the market.
Global Vasopressin Market Competitive Landscape
The "Global Vasopressin Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as Par Pharmaceutical, Pfizer, Novartis, Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma and Shanghai Soho-Yiming Pharmaceuticals. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis.
Customization of the Report
• In case of any queries or customization requirements please connect with our sales team, who will ensure that your requirements are met.
1. INTRODUCTION OF GLOBAL VASOPRESSIN MARKET
1.1. Overview of the Market
1.2. Scope of Report
1.3. Assumptions
2. EXECUTIVE SUMMARY
3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1. Data Mining
3.2. Validation
3.3. Primary Interviews
3.4. List of Data Sources
4. GLOBAL VASOPRESSIN MARKET OUTLOOK
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porters Five Force Model
4.4. Value Chain Analysis
5. GLOBAL VASOPRESSIN MARKET, BY PRODUCT TYPE
5.1. Overview
5.2. Intravenous Injection
5.3. Intramuscular Injection
5.4. Ubcutaneous Injection
6. GLOBAL VASOPRESSIN MARKET, BY APPLICATION
6.1. Overview
6.2. Anti-Diuretic Hormone Deficiency
6.3. Vasodilatory Shock
6.4. Gastrointestinal Bleeding
6.5. Ventricular Tachycardia & Fibrillation
7. GLOBAL VASOPRESSIN MARKET, BY GEOGRAPHY
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.3. Europe
7.3.1. Germany
7.3.2. U.K.
7.3.3. France
7.3.4. Rest of Europe
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. Rest of Asia Pacific
7.5. Rest of the World
8. GLOBAL VASOPRESSIN MARKET COMPETITIVE LANDSCAPE
8.1. Overview
8.2. Company Market Ranking
8.3. Key Development Strategies
9. COMPANY PROFILES
9.1. Par Pharmaceutical
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
9.2. Pfizer
9.2.1. Overview
9.2.2. Financial Performance
9.2.3. Product Outlook
9.2.4. Key Developments
9.3. Novartis
9.3.1. Overview
9.3.2. Financial Performance
9.3.3. Product Outlook
9.3.4. Key Developments
9.4. Ferring Pharmaceuticals
9.4.1. Overview
9.4.2. Financial Performance
9.4.3. Product Outlook
9.4.4. Key Developments
9.5. Fresenius Kabi Canada
9.5.1. Overview
9.5.2. Financial Performance
9.5.3. Product Outlook
9.5.4. Key Developments
9.6. Astellas Pharma
9.6.1. Overview
9.6.2. Financial Performance
9.6.3. Product Outlook
9.6.4. Key Developments
9.7. Shanghai Soho-Yiming Pharmaceuticals
9.7.1. Overview
9.7.2. Financial Performance
9.7.3. Product Outlook
9.7.4. Key Developments
10. Appendix
10.1. Related Reports